CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease

Open access
Hong, Jie, Zhang, Yifei, Lai, Shenghan, Lv, Ankang, Su, Qing, Dong, Yan, Zhou, Zhiguang, Tang, Weili, Zhao, Jiajun, Cui, Lianqun, Zou, Dajin, Wang, Dawang, Li, Hong, Liu, Chao, Wu, Guoting, Shen, Jie, Zhu, Dalong, Wang, Weiqing, Shen, Weifeng, Ning, Guang, on behalf of the SPREAD-DIMCAD Investigators · 2013 · Diabetes Care

Abstract

OBJECTIVE: The two major classes of antidiabetic drugs, sulfonylureas and metformin, may differentially affect macrovascular complications and mortality in diabetic patients. We compared the long-term effects of glipizide and metformin on the major cardiovascular events in type 2 diabetic patients who had a history of coronary artery disease (CAD). RESEARCH DESIGN AND METHODS: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 304 type 2 diabetic patients with CAD, mean age = 63.3 years (range, 36–80 years), were enrolled. Participants were randomly assigned to receive either glipizide (30 mg daily) or metformin (1.5 g daily) for 3 years. The primary end points were times to the composite of recurrent cardiovascular events, including death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke, or arterial revascularization. RESULTS: At the end of study drug administration, both groups achieved a significant decrease in the level of glycated hemoglobin (7.1% in the glipizide group and 7.0% in the metformin group). At a median follow-up of 5.0 years, 91 participants had developed 103 primary end points. Intention-to-treat analysis showed an adjusted hazard ratio (HR) of 0.54 (95% CI 0.30–0.90; P = 0.026) for the composites of cardiovascular events among the patients that received metformin, compared with glipizide. The secondary end points and adverse events were not significantly different between the two groups. CONCLUSIONS: Treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide. Our results indicated a potential benefit of metformin therapy on cardiovascular outcomes in high-risk patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-0719

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SPREAD-DIMCAD trial profile.
Figure 1 SPREAD-DIMCAD trial profile.CC BY-NC-ND · PubMed Central
Figure 2 Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. HbA1c (A), fasting plasma glucose (B), BMI (C), triglycerides (D), total cholesterol (E), LDL cholesterol (F), HDL cholesterol (G), and estimated glomerular filtration rate (eGFR) (H). Data displayed as means ± SD. P value refers to comparison between the groups.
Figure 2 Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. HbA1c (A), fasting plasma glucose (B), BMI (C), triglycerides (D), total cholesterol (E), LDL cholesterol (F), HDL cholesterol (G), and estimated glomerular filtration rate (eGFR) (H). Data displayed as means ± SD. P value refers to comparison between the groups.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 366

Metadata

Authors
Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., Zou, D., Wang, D., Li, H., Liu, C., Wu, G., Shen, J., Zhu, D., Wang, W., Shen, W., Ning, G., & on behalf of the SPREAD-DIMCAD Investigators
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Johns Hopkins University (US)
  • Second Xiangya Hospital of Central South University (CN)
  • Shandong University (CN)
  • Second Military Medical University (CN)
  • The First Affiliated Hospital of Wenzhou Medical College, Zhejiang Province, China
  • Sir Run Run Shaw Hospital (CN)
  • Jiangsu Province Hospital (CN)
  • Shanghai Ten’s People’s Hospital of Tongji University, Shanghai, China
  • Nanfang Hospital (CN)
  • Nanjing Drum Tower Hospital (CN)
Corresponding author
Ning, Guang
Venue
Diabetes Care
Published
2013-04-13
Volume
36
Issue
5
Pages
1304-1311
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2141199290
Cited by
366
References
37
Citations by year
2026: 7 · 2025: 16 · 2024: 20 · 2023: 26 · 2022: 43 · 2021: 35 · 2020: 44 · 2019: 31 · 2018: 31 · 2017: 28 · 2016: 30 · 2015: 20 · 2014: 22 · 2013: 12
FWCI
14.12
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81170784, 1994DP131044, 201002002, 2012ZX09303006-001, 30971077)
  • Shanghai Municipal Education Commission
  • National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (2012ZX09303006‐001)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
metformin, glipizide, type 2 diabetes, coronary artery disease, cardiovascular outcomes, sulfonylureas, myocardial infarction, stroke, cardiovascular mortality, HbA1c, macrovascular complications
MeSH terms
Adult, Aged, Aged, 80 and over, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glipizide, Humans, Male, Metformin, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. https://app.cochat.ai/papers/10.2337/dc12-0719
The paper
Hong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., Zou, D., Wang, D., Li, H., Liu, C., Wu, G., Shen, J., Zhu, D., Wang, W., Shen, W., . . . on behalf of the SPREAD-DIMCAD Investigators. (2013). Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease. Diabetes Care. https://doi.org/10.2337/dc12-0719

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.